Anti-TB Treatment in Pre-Existing Liver Disease

Background

Hepatotoxic Potential of First-Line Drugs

Regimen Selection Based on Liver Disease Severity

1. Mild–Moderate Liver Disease (stable): Remove PZA

PZA is frequently implicated in drug-induced liver injury (DILI) and is the first drug to drop.

• 2 months: INH + RIF + EMB
• 7 months: INH + RIF
• Total duration: 9 months

2. Significant Liver Disease: Remove INH + PZA

• RIF + EMB + fluoroquinolone (e.g., levofloxacin or moxifloxacin), ± cycloserine or injectable
• Duration: 12–18 months depending on disease extent and response

3. Alternative: Remove INH Only

• RIF + PZA + EMB ± fluoroquinolone
• Total duration: ≥6 months
• Retains two hepatotoxic drugs but maintains a shorter duration
• Based on outcomes from INH-resistant TB studies

4. Severe/Unstable Liver Disease: Minimize or Eliminate All Hepatotoxic Drugs

• EMB + fluoroquinolone + cycloserine + second-line injectable
• Duration: 18–24 months (similar to MDR-TB regimen)
• Avoid aminoglycosides in severe liver disease if there is renal insufficiency, thrombocytopenia, or coagulopathy risk

Baseline Assessment & Monitoring

• All patients: Baseline LFTs (ALT, AST, bilirubin) before starting therapy
• High-risk patients (liver disease, hepatitis C, daily alcohol use, older age): Monthly LFT monitoring during the initial phase
• Educate patients to self-report symptoms of hepatitis: dark urine, anorexia, nausea, right upper quadrant discomfort, jaundice

When to Stop Treatment (Drug-Induced Hepatitis Thresholds):

Re-introduction After DILI

1. RIF first (least likely to cause severe hepatitis) — wait 3–7 days
2. INH — wait another 3–7 days
3. PZA — add last (most hepatotoxic); often omitted entirely in patients with underlying liver disease

Special Considerations

Key Takeaways

• Tailor regimen intensity to the degree of liver compromise
• EMB + fluoroquinolone is the backbone of hepatotoxin-sparing regimens
• Longer treatment duration compensates for removing potent hepatotoxic bactericidal drugs
• Close LFT surveillance is mandatory in all patients with underlying liver disease
• Multidisciplinary involvement (hepatology + infectious disease) is ideal for severe cases

Anti-TB Treatment in Patients with Pre-Existing Liver Disease

1. Introduction

2. Hepatotoxic Potential of First-Line Anti-TB Drugs

2.1 Isoniazid (INH)

• Metabolized in the liver via N-acetyltransferase 2 (NAT2) to acetylhydrazine, which is further oxidized by CYP2E1 to toxic free radicals causing hepatocyte necrosis.
• Slow acetylators accumulate more hepatotoxic metabolites.
• Causes idiosyncratic hepatitis in ~0.1–2% of patients; rises to 10–20% in those with chronic liver disease.
• Clinical pattern: hepatocellular injury (elevated ALT/AST).

2.2 Rifampicin (RIF)

• Potent inducer of CYP450 enzymes, which accelerates INH metabolism to toxic intermediates — hence the synergistic hepatotoxicity when INH + RIF are combined.
• Primarily causes cholestatic pattern (raised bilirubin, ALP).
• Causes transient, asymptomatic rise in transaminases in up to 20% of patients that often resolves spontaneously.

2.3 Pyrazinamide (PZA)

• Most hepatotoxic of the three; causes dose-dependent hepatocellular injury.
• Metabolized to pyrazinoic acid, which inhibits mitochondrial electron transport.
• Overall DILI incidence: ~1–5%; higher in those with underlying liver disease.
• Most frequently implicated drug when all three are used together.

2.4 Ethambutol (EMB)

• Not hepatotoxic; primarily renally excreted.
• Primary toxicity: optic neuritis (dose-related; monitor visual acuity and color discrimination).
• Safe to use in all degrees of liver impairment.

2.5 Fluoroquinolones (Levofloxacin, Moxifloxacin)

• Mild hepatotoxic potential; rarely cause significant DILI.
• Valuable additions in hepatotoxin-sparing regimens.

3. Risk Factors for Anti-TB DILI

• Pre-existing liver disease: chronic hepatitis B or C, alcoholic liver disease, NAFLD, cirrhosis
• Daily alcohol consumption
• Older age (>35 years)
• Malnutrition and low albumin
• HIV co-infection
• Slow NAT2 acetylator genotype
• Female sex
• Concurrent use of other hepatotoxic drugs (e.g., antiretrovirals)
• Baseline elevated transaminases

4. Definition of Anti-TB Drug-Induced Liver Injury (DILI)

1. ALT ≥ 3× ULN in the presence of symptoms (nausea, anorexia, fatigue, jaundice, fever, rash)
2. ALT ≥ 3× ULN + total bilirubin ≥ 2× ULN, even without symptoms
3. ALT ≥ 5× ULN alone, even without symptoms

Hy's Law: ALT >3× ULN + bilirubin >2× ULN (without cholestasis) — predicts a ~10% risk of fatal drug-induced hepatic failure.

5. Pre-Treatment Baseline Assessment

• Liver function tests: ALT, AST, ALP, GGT, total and direct bilirubin
• Serum albumin and PT/INR (markers of synthetic function)
• CBC (thrombocytopenia in cirrhosis)
• Hepatitis B surface antigen (HBsAg) and anti-HCV antibody — identify viral co-infection
• Renal function (guides drug dosing and aminoglycoside safety)
• Abdominal ultrasound if cirrhosis is suspected

6. Modified Anti-TB Regimens Based on Liver Disease Severity

Regimen 1 — Mild/Stable Liver Disease: Omit PZA

PZA is the most hepatotoxic drug and the first to be dropped.

• Retains INH and RIF — the two most bactericidal drugs
• Suitable for: chronic hepatitis (stable), mild fatty liver, Child-Pugh A cirrhosis

Regimen 2 — Moderate Liver Disease: Omit INH + PZA

Removes both the most idiosyncratic (INH) and most dose-toxic (PZA) hepatotoxins.

• Based on outcomes from INH-resistant TB studies
• Longer duration compensates for loss of bactericidal INH
• Suitable for: Child-Pugh B cirrhosis, decompensated chronic hepatitis B/C

Regimen 3 — Alternative Moderate Disease: Omit INH Only

• Advantage: retains short duration (6 months)
• Disadvantage: still contains two hepatotoxic agents (RIF + PZA)
• Use only when liver function can be closely monitored

Regimen 4 — Severe/Unstable Liver Disease: Hepatotoxin-Free Regimen

Reserved for acute liver failure, Child-Pugh C cirrhosis, or fulminant hepatitis.

• Modelled on MDR-TB regimens
• Avoid aminoglycosides if the patient has: renal impairment, coagulopathy, or thrombocytopenia (bleeding risk at injection site)
• Suitable for: acute viral hepatitis, decompensated cirrhosis, hepatic failure

Summary Table: Regimen Selection

7. Monitoring During Treatment

• All patients: Monthly LFTs during the initial phase if at-risk (liver disease, HCV, daily alcohol)
• Symptom-based monitoring: Instruct all patients to discontinue treatment and seek care if:
  • Dark/cola-colored urine
  • Jaundice (yellow eyes/skin)
  • Anorexia, nausea, vomiting
  • Right upper quadrant pain
  • Unusual fatigue

Action Thresholds:

• While hepatotoxic drugs are held, continue with safe substitutes: EMB + fluoroquinolone ± streptomycin to prevent disease progression
• Resume hepatotoxic drugs only after LFTs return to baseline or <2× ULN

8. Sequential Drug Reintroduction (Rechallenge) After DILI

1. Rifampicin — reintroduce first (least likely to cause severe hepatitis); wait 3–7 days and recheck LFTs
2. Isoniazid — add next if LFTs remain stable; wait another 3–7 days
3. Pyrazinamide — add last, and only if truly necessary; if DILI recurs on PZA, omit it permanently and extend treatment duration

If DILI recurs with rechallenge, identify the offending drug and eliminate it permanently from the regimen, replacing it with a safe alternative.

9. Special Clinical Scenarios

9.1 Chronic Hepatitis B (HBV) Co-infection

• Screen all TB patients for HBsAg before starting treatment
• Rifampicin and INH can cause HBV reactivation flares in HBV carriers
• If antiviral therapy is indicated (high HBV DNA, active disease): start tenofovir or entecavir concurrently
• Prefer tenofovir (dual activity against HBV + avoids tenofovir–rifampicin interactions in HIV co-infection)
• Per Harrison's (p. 9590): tenofovir and entecavir are preferred due to lower resistance risk

9.2 Chronic Hepatitis C (HCV) Co-infection

• HCV patients have the highest risk of anti-TB DILI
• Monthly LFTs are mandatory
• Direct-acting antivirals (DAAs) for HCV should be coordinated carefully — significant drug interactions exist between rifampicin (CYP inducer) and most DAAs; rifampicin should ideally be replaced if HCV treatment is planned

9.3 Alcoholic Liver Disease

• Daily alcohol intake is an independent risk factor for DILI
• Abstinence counseling is essential before and during TB treatment
• Use PZA-sparing regimens (Regimen 1 or 2 above)

9.4 Acute Viral Hepatitis

• If TB is not immediately life-threatening, defer TB treatment until acute hepatitis resolves
• If TB requires urgent treatment (e.g., miliary TB, TBM): use hepatotoxin-free regimen (Regimen 4) until hepatitis resolves, then switch to standard or modified regimen

9.5 HIV Co-infection with Liver Disease

• Antiretrovirals (especially NRTIs like stavudine, didanosine; NNRTIs like nevirapine) are independently hepatotoxic — significantly increases DILI risk in triple-threat: HIV + TB + liver disease
• Rifampicin is a strong CYP3A4 inducer — markedly reduces levels of most protease inhibitors; rifabutin is preferred if a PI-based ART regimen is used
• Avoid nevirapine with rifampicin; prefer efavirenz with rifampicin-based TB regimens

10. Role of Steroids and Hepatoprotective Agents

• Corticosteroids: indicated for specific TB complications (TB meningitis, TB pericarditis) — no role in preventing DILI
• Hepatoprotective agents (silymarin/milk thistle, N-acetylcysteine, UDCA): insufficient evidence to recommend routinely; sometimes used empirically in patients with borderline LFTs to allow continuation of therapy
• N-acetylcysteine: considered in severe DILI (free radical scavenging), not yet standard practice

11. Overall Management Algorithm

Patient with TB + Pre-existing Liver Disease
            |
Assess severity of liver disease
            |
    ┌───────────────────────────────────┐
    │                                   │
  Mild/Stable               Moderate–Severe
(Child-Pugh A)            (Child-Pugh B/C or
                          Acute Hepatitis)
    │                               │
  Omit PZA               Omit INH+PZA or
  (9-month                All hepatotoxic
  INH+RIF+EMB)            drugs (18–24 mo)
    │                               │
Monthly LFT monitoring ──────────────┘
    │
  DILI detected?
    │
  Stop drugs → Safe substitutes (EMB+FQ)
    │
  LFTs normalize → Sequential rechallenge
    │
  Identify culprit → Exclude permanently

12. Key Takeaways for Exam

1. PZA is the most hepatotoxic first-line drug and the first to be removed in liver disease.
2. EMB + fluoroquinolone is the backbone of safe, hepatotoxin-free regimens.
3. Omitting drugs extends treatment duration: no PZA → 9 months; no INH+PZA → 12–18 months; no hepatotoxic drug → 18–24 months.
4. Baseline LFTs are mandatory in all patients; monthly monitoring is required in high-risk patients.
5. Drugs should be stopped when ALT >3× ULN with symptoms, or >5× ULN without symptoms.
6. Sequential rechallenge: RIF → INH → PZA (last and often permanently omitted in liver disease).
7. HBV co-infection: screen all, add tenofovir/entecavir if indicated; watch for reactivation.
8. Rifampicin interacts with HCV DAAs and most ART protease inhibitors — coordinate carefully.
9. Multidisciplinary care (hepatology + pulmonology/ID) is recommended for severe cases.
10. If acute hepatitis is present and TB is not life-threatening — defer TB treatment until liver recovers.